ARG81929
Human CD274 / PD-L1 ELISA Kit
Human CD274 / PD-L1 ELISA Kit for ELISA and Human
Publication2
Component
| Cat No | Component Name | Package | Temp |
|---|---|---|---|
| ARG81929-001 | Antibody-coated microplate | 8 X 12 strips | 4°C. Unused strips should be sealed tightly in the air-tight pouch. |
| ARG81929-002 | Standard | 2 X 10 ng/vial | 4°C |
| ARG81929-003 | Standard/Sample diluent | 30 ml (Ready to use) | 4°C |
| ARG81929-004 | Antibody conjugate concentrate (100X) | 1 vial (130 µl) | 4°C |
| ARG81929-005 | Antibody diluent buffer | 12 ml (Ready to use) | 4°C |
| ARG81929-006 | HRP-Streptavidin concentrate (100X) | 1 vial (130 µl) | 4°C |
| ARG81929-007 | HRP-Streptavidin diluent buffer | 12 ml (Ready to use) | 4°C |
| ARG81929-008 | 25X Wash buffer | 20 ml | 4°C |
| ARG81929-009 | TMB substrate | 10 ml (Ready to use) | 4°C (Protect from light) |
| ARG81929-010 | STOP solution | 10 ml (Ready to use) | 4°C |
| ARG81929-011 | Plate sealer | 4 strips | Room temperature |
Overview
| Product Description | ARG81929 Human CD274 / PD-L1 ELISA Kit is an Enzyme Immunoassay kit for the quantification of Human CD274 / PD-L1 in serum, plasma (heparin, EDTA) and cell culture supernatants. |
|---|---|
| Tested Reactivity | Hu |
| Tested Application | ELISA |
| Specificity | There is no detectable cross-reactivity with other relevant proteins. |
| Target Name | CD274 / PD-L1 |
| Conjugation | HRP |
| Conjugation Note | Substrate: TMB and read at 450 nm. |
| Sensitivity | 31.25 pg/ml |
| Sample Type | Serum, plasma (heparin, EDTA) and cell culture supernatants. |
| Standard Range | 62.5 - 4000 pg/ml |
| Sample Volume | 100 µl |
| Precision | Intra-Assay CV: 4.7%; Inter-Assay CV: 6.0% |
| Alternate Names | Programmed cell death 1 ligand 1; B7-H1; B7H1; PDL1; PDCD1 ligand 1; B7 homolog 1; PD-L1; CD antigen CD274; PDCD1L1; B7-H; Programmed death ligand 1; PDCD1LG1 |
Application Instructions
| Assay Time | ~ 5 hours |
|---|
Properties
| Form | 96 well |
|---|---|
| Storage Instruction | Store the kit at 2-8°C. Keep microplate wells sealed in a dry bag with desiccants. Do not expose test reagents to heat, sun or strong light during storage and usage. Please refer to the product user manual for detail temperatures of the components. |
| Note | For laboratory research only, not for drug, diagnostic or other use. |
Bioinformation
| Database Links | |
|---|---|
| Gene Symbol | CD274 |
| Gene Full Name | CD274 molecule |
| Background | CD274 / PD-L1 is an immune inhibitory receptor ligand. It is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015] |
| Function | CD274 / PD-L1 plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077). The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813410). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy. [UniProt] |
| Highlight | Related products: PD-L1 antibodies; PD-L1 ELISA Kits; Related news: Detecting exosomal PD-L1 secreted by cancer cells The best solution for PD-1/PD-L1 research Examining CTL/NK-mediated cytotoxicity by ELISA New ELISA data calculation tool: Simplify the ELISA analysis by GainData |
Images (1) Click the Picture to Zoom In
-
ARG81929 Human CD274 / PD-L1 ELISA Kit standard curve image
ARG81929 Human CD274 / PD-L1 ELISA Kit results of a typical standard run with optical density reading at 450 nm.
Specific References
Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.
ELISA / Human
Clinical Significance of Serum-derived Exosomal PD-L1 in Patients with Resected Non-small Cell Lung Cancer.
ELISA / Human / Serum
| Title | Download Link |
|---|---|
| ARG81929 Human CD274 / PD-L1 ELISA Kit User's manual |
 Download
|
